Global Patent Index - EP 2648730 A2

EP 2648730 A2 20131016 - COMPLEX FORMULATION COMPRISING LERCANIDIPINE HYDROCHLORIDE AND VALSARTAN AND METHOD FOR THE PREPARATION THEREOF

Title (en)

COMPLEX FORMULATION COMPRISING LERCANIDIPINE HYDROCHLORIDE AND VALSARTAN AND METHOD FOR THE PREPARATION THEREOF

Title (de)

KOMPLEXE FORMULIERUNG MIT LERCANIDIPIN-HYDROCHLORID UND VALSARTAN SOWIE VERFAHREN ZU IHRER HERSTELLUNG

Title (fr)

FORMULATION COMPLEXE CONTENANT DE L'HYDROCHLORURE DE LERCANIDIPINE ET DU VALSARTAN ET SON PROCÉDÉ DE PRÉPARATION

Publication

EP 2648730 A2 20131016 (EN)

Application

EP 11847739 A 20111207

Priority

  • KR 20100125804 A 20101209
  • KR 2011009413 W 20111207

Abstract (en)

[origin: WO2012077968A2] The present invention relates to a pharmaceutical composition comprising lercanidipine hydrochloride and valsartan as active components and a method for the preparation thereof. The pharmaceutical composition comprising lercanidipine hydrochloride and valsartan according to the present invention has a superior effect on the prevention and treatment of cardiovascular diseases and their complex diseases, and reduces the adverse effects of each component. In addition, the present composition comprises lercanidipine hydrochloride and valsartan in a separated form so as to increase the dissolution rates of both components and reduce the adverse effects.

IPC 8 full level

A61K 9/16 (2006.01); A61K 9/50 (2006.01); A61K 31/41 (2006.01); A61K 31/4422 (2006.01); A61P 9/00 (2006.01)

CPC (source: EP KR)

A61K 9/16 (2013.01 - KR); A61K 9/1635 (2013.01 - EP); A61K 9/1652 (2013.01 - EP); A61K 9/2027 (2013.01 - EP); A61K 9/2054 (2013.01 - EP); A61K 9/209 (2013.01 - EP); A61K 9/2095 (2013.01 - EP); A61K 9/5084 (2013.01 - EP); A61K 31/41 (2013.01 - EP KR); A61K 31/4422 (2013.01 - EP KR); A61P 9/00 (2017.12 - EP); A61P 9/12 (2017.12 - EP)

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2012077968 A2 20120614; WO 2012077968 A3 20120726; AR 084195 A1 20130424; AU 2011339150 A1 20130606; AU 2011339150 B2 20150910; BR 112013013415 A2 20190924; CL 2013001626 A1 20131004; CN 103249415 A 20130814; CN 103249415 B 20171212; CO 6721030 A2 20130731; DO P2013000115 A 20140731; EA 201390844 A1 20131129; EP 2648730 A2 20131016; EP 2648730 A4 20140806; IL 226449 A0 20130731; KR 101414814 B1 20140721; KR 20120089787 A 20120813; MX 2013005716 A 20130612; PE 20140699 A1 20140613; SG 190326 A1 20130628; UA 108277 C2 20150410; UY 33772 A 20120731

DOCDB simple family (application)

KR 2011009413 W 20111207; AR P110104583 A 20111207; AU 2011339150 A 20111207; BR 112013013415 A 20111207; CL 2013001626 A 20130606; CN 201180058951 A 20111207; CO 13147794 A 20130621; DO 2013000115 A 20130521; EA 201390844 A 20111207; EP 11847739 A 20111207; IL 22644913 A 20130520; KR 20110130400 A 20111207; MX 2013005716 A 20111207; PE 2013001346 A 20111207; SG 2013038211 A 20111207; UA A201307936 A 20111207; UY 33772 A 20111206